Registration Header
REGISTER TODAY!

CytomX Virtual Investor Event

Start Date:4/7/2021

Start Time:1:00 PM EDT

Duration:120 minutes

Abstract:

Virtual presentation of the company’s Probody technology platform with a focus on praluzatamab ravtansine (CX-2009) and CX-2029, featuring industry experts and CytomX leadership.

If you're already registered for the CytomX Virtual Investor Event webcast, click below:

ALREADY REGISTERED?

Speakers

Sean A. McCarthy

President, Chief Executive Officer and Chairman

CytomX Therapeutics

Dr. McCarthy joined CytomX in December 2010 as our chief business officer and became a member of our board of directors and our president and chief executive officer in August 2011. On January 1, 2019, Dr. McCarthy became chairman of our board of directors. Dr. McCarthy has more than twenty years of experience in the biotechnology industry encompassing roles in R&D, business development, financing and general management. Following completion of his post-doctoral training at the DNAX Research Institute (now Merck Palo Alto), Dr. McCarthy held research leadership and program management roles at Millennium Pharmaceuticals where he managed biologics discovery programs. From Millennium, Dr. McCarthy joined SGX Pharmaceuticals, where he spearheaded a wide range of large pharma partnerships as vice president business development and helped drive a strategic reorientation of the company from a platform business model to product-focused oncology company, leading to a successful initial public offering in 2006. Immediately prior to joining CytomX, Dr. McCarthy was a transactional partner at Pappas Ventures from April 2006 to December 2010, where he was responsible for investments in therapeutic, medical device and molecular diagnostic companies. Dr. McCarthy is an author on multiple peer reviewed scientific publications, issued patents and filed patent applications. He received a B.Sc. in biochemistry and pharmacology at King’s College, University of London; an MBA from the Rady School of Management at the University of California San Diego; and a D.Phil. in cancer biology from St. John’s College, University of Oxford. Dr. McCarthy currently serves as a member of the Board of Directors and the Executive Committee of the California Life Sciences Association.

Amy C. Peterson

EVP, Chief Development Officer

CytomX Therapeutics

Amy Peterson, M.D. joined CytomX in October 2019 as executive vice president and chief development officer. Prior to joining CytomX, Dr. Peterson was chief medical officer of immuno-oncology at BeiGene, Ltd. where she created and led a global oncology development organization with direct medical oversight and accountability of 7 clinical assets in over thirty global trials in all phases of development in solid tumor indications. Prior to BeiGene, Dr. Peterson was vice president of clinical development at Medivation where she was primarily responsible for the development of enzalutamide (XTANDI®) and talazoparib (TALZENNA®) in breast cancer. Previously, Dr. Peterson served as associate group medical director at Genentech, where she was responsible for the development of early stage molecules targeting multiple major pathways in oncology. Prior to joining Genentech, Dr. Peterson was an Instructor of Medicine in Oncology at the University of Chicago, where she conducted translational research in tumor immunology in conjunction with Dr. Thomas F. Gajewski. She currently serves on the board of The American Society of Clinical Oncology’s (ASCO) Conquer Cancer Foundation. Dr. Peterson received her M.D. from Thomas Jefferson University and completed her residency in Internal Medicine at Northwestern Memorial Hospital and Fellowship in Hematology and Oncology at the University of Chicago. Dr. Peterson received her B.A. degree from Wesleyan University.

Marcia P. Belvin, Ph.D.

SVP, Head of Research

CytomX Therapeutics

Dr. Belvin joined CytomX in 2018. Prior to this, Dr. Belvin held roles of increasing responsibility at Genentech where, over 13 years, she led multiple preclinical pipeline teams and oversaw programs in cancer signaling, cancer metabolism, and cancer immunology. Dr. Belvin began her career at Exelixis where she managed teams responsible for preclinical pipeline discovery within the oncology and inflammation portfolios. Dr. Belvin received her B.A. degree from Harvard University and her Ph.D. from the University of California, Berkeley. Dr. Belvin also trained at the Dana-Farber Cancer Institute and Cold Spring Harbor Laboratory.

John Lambert

Consultant/Scientific Advisor to CytomX Therapeutics

Honorary Professor, Queen’s University Belfast, Northern Ireland, UK

Dr. Lambert graduated from Christ’s College, University of Cambridge (England, UK), with a degree in Natural Sciences in 1972. He then earned a Ph.D. in Biochemistry from the University of Cambridge in 1976, working on the structure of glycolytic enzymes under the supervision of Professor Richard N. Perham. Dr Lambert’s postdoctoral training was at the University of California, Davis (1976-1980), working on ribosome structure in the laboratory of Dr Robert R. Traut, and at the University of Glasgow, Scotland (1980-1982), working on the arom multienzyme complex in the laboratory of Dr John R. Coggins. In 1982, Dr. Lambert joined the Dana-Farber Cancer Institute, Harvard Medical School, working on the ImmunoGen-funded programs to develop antibody-drug conjugates (ADCs) and immunotoxins as anti-cancer therapeutics. Dr. Lambert joined ImmunoGen in 1987 when the company established independent research laboratories in Cambridge, Massachusetts. After working in a variety of roles at the company, Dr. Lambert served as Chief Scientific Officer from 2008 until 2015. In 2016, he became a Distinguished Research Fellow at the company until his retirement at the end of 2017. He served on the Executive Committee of the company as Executive Vice President, Research, from 2008 until 2016, followed by a year (2017) on the Executive Committee in an Emeritus capacity until retirement. During Dr Lambert’s tenure in leadership roles at ImmunoGen, the company invented the ADC technology that resulted in the Genentech/Roche drug, Kadcyla® (approved in 2013 for treating HER2+ breast cancer), as well as numerous other ADCs taken into clinical development. One of these is ImmunoGen’s promising drug candidate, mirvetuximab soravtansine, an ADC currently in pivotal trials for the treatment of platinum-resistant ovarian cancer. Dr Lambert is the author/co-author of over 125 peer-reviewed scientific publications. In 2016, Dr Lambert was elected as a Fellow of the American Institute for Medical and Biological Engineering (AIMBE). In 2018, he was appointed as an Honorary Professor of Queen’s University Belfast, Northern Ireland, UK.

Sara Tolaney

Associate Director, Susan F. Smith Center for Women’s Cancers

Director, Clinical Trials, Breast Oncology, Dana-Farber Cancer Institute

Sara Tolaney, MD, MPH is a breast medical oncologist at Dana-Farber Cancer Insitute. Dr. Tolaney has earned both a strong national and international reputation as a talented clinical investigator and is key opinion leader in breast oncology. She has done extensive work on de-escalating therapy for patients with low-risk HER2-positive breast cancer, having developed a less toxic treatment regimen associated with a clinically low event rate. This regimen is incorporated into national and international treatment guidelines, and she has follow-up multi-institutional studies ongoing to evaluate if even less toxic therapies may have a role in these patients. She also been instrumental in the development of cdk 4/6 inhibitors in breast cancer, and is currently the PI for the ongoing adjuvant trial of abemaciclib in hormone-receptor positive HER2+ breast cancer. Moreover, she has played a pivotal role in developing a series of investigator initiated clinical trials in immunotherapy, with strong translational endpoints, and serves as the Director for Breast Immunotherapy Clinical Research at DFCI. Dr. Tolaney has also been instrumental in overseeing the Breast Oncology Clinical Trials program, one of the largest clinical research programs at DFCI. Additionally, she serves as the Associate Director of the Susan F. Smith Center for Women’s Cancers, and chairs the Scientific Steering Committee for this group. Importantly, Dr. Tolaney is also an outstanding clinician, recognized by her peers for her excellent patient care with the “Lee Nadler Extra Mile Award” and is a Senior Physician at DFCI. Dr. Tolaney received her undergraduate degree from Princeton University in 1998 and her medical degree from UC San Francisco in 2002. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained a Masters in Public Health from the Harvard School of Public Health in 2007.

Melissa L Johnson

Director, Lung Cancer Research

Sarah Cannon Research Institute

Dr. Johnson serves as the director of lung cancer research program at Sarah Cannon. Her responsibilities include supporting the growth of the phase 2/3 Lung Program clinical trial portfolio, while also furthering the development of early phase compounds for thoracic malignancies in the drug development unit. Dr. Johnson received her undergraduate degree from the University of North Carolina, Chapel Hill and her medical degree from the University of Pennsylvania. She completed her residency in internal medicine at New York Presbyterian/Weill Cornell Medical Center and her fellowship in medical oncology and hematology at Memorial Sloan Kettering Cancer Center where she also served as chief fellow for one year. She spent four years as a faculty member at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Feinberg School of Medicine, where she was a founding member of the Northwestern Medical Developmental Therapeutics Institute (NMDTI). She is board certified in internal medicine and medical oncology. Additionally, she is an associate with Tennessee Oncology, PLLC.
First Name
Last Name
Email Address
Company
Job Title